Showing 1231-1240 of 5603 results for "".
MIRASOL Insights in PROC: A Biomarker-Driven Approach
https://reachmd.com/programs/project-oncology/mirasol-proc-biomarker-approach/37252/In platinum-resistant ovarian cancer (PROC), survival is usually measured in months,1-3 and most patients will have already received multiple prior lines of therapy.4 Biomarker-driven therapy has helped change the treatment landscape.5-10 Tune in to learn more about mirvetuximab soravtansine-gynx asExpanding Treatment Options in PNH: Expert Approaches to Personalized Care
https://reachmd.com/programs/medical-industry-feature/pnh-expert-approaches-personalized-care/35651/Managing patients with paroxysmal nocturnal hemoglobinuria (PNH) is never a “one-size-fits-all” approach. With the emergence of a therapy like FABHALTA® (iptacopan), which delivers comprehensive control of intravascular and extravascular hemolysis, we have an option to offer to eligible adult patienLong-Term PNH Management: Addressing Treatment Goals Beyond Symptom Control
https://reachmd.com/programs/medical-industry-feature/long-term-pnh-management-treatment-goals/35652/Patients with paroxysmal nocturnal hemoglobinuria (PNH) require lifelong therapy.1,2 Long-term data on an available treatment option can help address patient goals—not only in treating symptoms, but also long-term complications. Hear from Arati Chand, MD and Bhumika Patel, MD as they review two-yearPersonalizing PNH Care: Exploring the Role of Iptacopan in Clinical Practice
https://reachmd.com/programs/medical-industry-feature/personalizing-pnh-care-iptacopan/35650/While patients with paroxysmal nocturnal hemoglobinuria (PNH) share the same diagnosis, they show a range of hemoglobin levels and symptoms.1,2 C5 inhibitors have reduced mortality and morbidity in patients with PNH, but FABHALTA® (iptacopan) may offer another treatment option that can match individMoving Beyond Hesitation: Exploring an Oral Option for Managing PNH
https://reachmd.com/programs/medical-industry-feature/oral-option-paroxysmal-nocturnal-hemoglobinuria/35649/It wasn’t that long ago that patients diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) had limited treatment options;1 however, even with more options available, hesitancy to start therapy, particularly complement inhibition, still exists for some patients. As a result, knowing how to communRewiring Your Thinking in Paroxysmal Nocturnal Hemoglobinuria
https://reachmd.com/programs/medical-industry-feature/rewiring-your-thinking-in-paroxysmal-nocturnal-hemoglobinuria/35648/As of the past few years, there are more options to consider when treating adult patients with paroxysmal nocturnal hemoglobinuria (PNH).1-5 Some providers note that in light of these shifts, they can focus on tailoring their treatment decisions to fit the specific needs of their patients. Join StevEpilepsy Essentials: Practical Uses of EEG in the Operating Room
https://reachmd.com/diseases-diagnoses/epilepsy-seizures/epilepsy-essentials-practical-uses-of-eeg-in-the-operating-room/37660/Intraoperative EEG monitoring of brain function during surgical procedures acquires real-time electrophysiologic signals and provides immediate feedback to the surgeon.How COVID-19 Is Affecting Children Physically, Mentally, & Emotionally
https://reachmd.com/programs/covid-19-frontlines/how-covid-19-is-affecting-children-physically-mentally-emotionally/11634/From the newly recognized condition known as MISC to anxiety, a pediatrician shares all the different ways the pandemic is affecting young patients.E-cigarettes: An Emerging Public Health Challenge
https://reachmd.com/programs/grand-rounds-nation/e-cigarettes-emerging-public-health-challenge/7719/Electronic cigarettes, or e-cigarettes, are an emerging challenge for public health. These devices are part of a growing landscape of electronic nicotine delivery systems (ENDS) that includes many different types of products, such as vape pens and e-hookahs. Despite differences in appearance, theseThe Dermatology and Aesthetics Mergers and Acquisitions Market: Reflecting on Trends, Looking ahead
https://reachmd.com/ma-issues-index/2025-mar-apr/the-dermatology-and-aesthetics-mergers-and-acquisitions-market-reflecting-on-trends-looking-ahead/36070/As we look ahead to 2025, dermatology and aesthetic practice owners are asking a key question: What lies ahead for practice valuations and M&A opportunities?